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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERPublic Reporting of Clinical Quality Data 1239
Gregory J. Dehmer, Joseph P. Drozda, Jr, Ralph G. Brindis, Frederick A. Masoudi, John S. Rumsfeld,
Lara E. Slattery, William J. Oetgen
In the United States, the ﬁrst national public reports of hospital mortality data occurred in
1986, and detailed physician-level data for cardiac surgery are now reported in 4 states.
The development of the “Hospital Compare” and more recently the “Physician Compare”
websites has further expanded public reporting for hospitals and providers. Dehmer and
colleagues review the utility and pitfalls of public reporting and conclude that more research is
needed to both better deﬁne meaningful reporting measures and to determine the impact of
public reporting on healthcare delivery.WORKGROUP REPORT WORKGROUP REPORTClassiﬁcation System for Patients With Heart Failure and ESRD 1246Lakhmir S. Chawla, Charles A. Herzog, Maria Rosa Costanzo, James Tumlin, John A. Kellum,
Peter A. McCullough, Claudio Ronco, for the ADQI XI Workgroup
With rare exceptions, patients with end-stage renal disease (ESRD) who do not receive
timely and adequate renal replacement therapy (RRT) develop signs and symptoms of heart
failure with ﬂuid overload. Neither the American Heart Association/American College of
Cardiology heart failure staging nor the New York Heart Association functional classiﬁcation
system identiﬁes the variable symptomatology that ESRD patients experience. The 11th
Acute Dialysis Quality Initiative has identiﬁed this issue as a critical unmet need for the
proper evaluation and treatment of heart failure in patients with ESRD. The authors propose
a classiﬁcation schema based on patient-reported dyspnea assessed both pre- and
post-ultraﬁltration, in conjunction with echocardiography.(continued on page A-26)
APRIL 8, 2014 (continued)CLINICAL RESEARCHA-26CORONARY ARTERY DISEASEComparison of iFR and Pd/Pa Versus FFR 1253
Allen Jeremias, Akiko Maehara, Philippe Généreux, Kaleab N. Asrress, Colin Berry, Bernard De Bruyne,
Justin E. Davies, Javier Escaned, William F. Fearon, K. Lance Gould, Nils P. Johnson, Ajay J. Kirtane,
Bon-Kwon Koo, Koen M. Marques, Sukhjinder Nijjer, Keith G. Oldroyd, Ricardo Petraco, Jan J. Piek,
Nico H. Pijls, Simon Redwood, Maria Siebes, Jos A. E. Spaan, Marcel van ’t Veer, Gary S. Mintz,
Gregg W. Stone
Jeremias and colleagues compared the diagnostic accuracy of instantaneous wave-free ratio
(iFR) and resting ratio of distal coronary artery pressure to aortic pressure (Pd/Pa) with the
current gold standard, hyperemic fractional ﬂow reserve (FFR). Pd/Pa is the ratio of these
pressures over the entire cardiac cycle, whereas the instantaneous wave-free ratio (iFR)
measures this ratio during a speciﬁc period of diastole; neither requires pharmacological
hyperemia. iFR, Pd/Pa, and FFR were measured in 1,768 patients from 15 clinical sites by an
independent core laboratory. By receiver-operating characteristic curve analysis, the optimal
iFR cut point for FFR 0.80 was 0.90 (c-statistic: 0.81, overall accuracy 80%), and the
optimal cut point for Pd/Pa was 0.92 (c-statistic: 0.82, overall accuracy 82%), with no
signiﬁcant difference between these resting measures. iFR and Pd/Pa had 90% accuracy to
predict a positive or negative FFR in 65% and 48% of patients, suggesting that adenosine
infusion can be avoided in two-thirds and one-half of patients, respectively.
Editorial Comment: Francis J. Klocke, p. 1262CORONARY ARTERY DISEASEYield of Imaging After Standard Exercise Treadmill Testing 1264
Mitalee P. Christman, Marcio Sommer Bittencourt, Edward Hulten, Ekta Saksena, Jon Hainer,
Hicham Skali, Raymond Y. Kwong, Daniel E. Forman, Sharmila Dorbala, Patrick T. O’Gara,
Marcelo F. Di Carli, Ron Blankstein
Christman and colleagues sought to determine the frequency and results of downstream
testing following exercise treadmill testing (ETT). The records of 3,345 consecutive
individuals without known coronary artery disease referred for clinical ETT were reviewed.
Nine percent of subjects underwent subsequent noninvasive imaging, and 2.3% were referred
directly to invasive angiography. The annual incidence of the combined endpoint of survival
free from cardiovascular death, myocardial infarction, and coronary revascularization
following negative, inconclusive, and positive ETT was 0.2%, 1.3%, and 12.4%, respectively
(p < 0.001). Rapid recovery of electrocardiographic changes after exercise was associated with
negative downstream test results and excellent prognosis, whereas typical angina despite a
negative electrocardiogram was associated with positive downstream tests and adverse
prognosis (p < 0.001). These ﬁndings may be used to identify patients who are most and
least likely to beneﬁt from additional testing after ETT.
Editorial Comment: Albert J. Sinusas, Erica S. Spatz, p. 1275(continued on page A-30)
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Frederick J. Raal, Robert P. Giugliano, Marc S. Sabatine, Michael J. Koren, Gisle Langslet, Harold Bays,
Dirk Blom, Mats Eriksson, Ricardo Dent, Scott M. Wasserman, Fannie Huang, Allen Xue,
Moetaz Albizem, Rob Scott, Evan A. Stein
Lipoprotein(a) [Lp(a)], a low-density lipoprotein (LDL) particle linked to the
plasminogen-like glycoprotein apolipoprotein(a), shows a consistent and independent
positive association with cardiovascular disease risk in epidemiological studies. Current
therapeutic options to reduce Lp(a) are limited. Raal and colleagues performed a pooled
analysis of 4 trials to assess the effect of the proprotein convertase subtilisin/kexin type 9
(PCSK9) monoclonal antibody evolocumab (AMG 145) on Lp(a). Evolocumab treatment
for 12 weeks resulted in signiﬁcant dose-related reductions in Lp(a) compared with the
control group. Lp(a) reductions were signiﬁcantly correlated with percentage reductions in
LDL-C and apolipoprotein B. Inhibition of PCSK9 with evolocumab produces signiﬁcant
reduction in Lp(a) in addition to LDL and apolipoprotein B.PLATELET FUNCTIONRBC Transfusion Stimulates Platelet Aggregation 1289
Johanne Silvain, Jérémie Abtan, Mathieu Kerneis, Réjane Martin, Jonathan Finzi,
Jean-Baptiste Vignalou, Olivier Barthélémy, Stephen A. O’Connor, Charles-Edouard Luyt,
Nicolas Brechot, Anne Mercadier, Delphine Brugier, Sophie Galier, Jean-Philippe Collet, Jean Chastre,
Gilles Montalescot
Silvain and colleagues examined whether red blood cell (RBC) transfusion increases in vivo
platelet aggregation and inﬂammation. Platelet reactivity was measured before and after RBC
transfusion in 33 patients with an acute coronary syndrome (ACS) and in 28 patients without
ACS. After RBC transfusion, platelet reactivity was increased when measured with adenosine
diphosphate (ADP)-induced light transmission aggregometry and vasodilator-stimulated
phosphoprotein platelet reactivity index. There were no signiﬁcant differences in
inﬂammatory and thrombotic biomarkers before and after transfusion. After RBC
transfusion, there was an increase in platelet reactivity, especially with tests measuring the
ADP-P2Y12 receptor pathway; this may account for the increased ischemic events with
transfusion observed in the context of ACS treated by P2Y12 inhibitors.
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Andrea Mazzanti, Ajita Kanthan, Nicola Monteforte, Mirella Memmi, Raffaella Bloise, Valeria Novelli,
Carlotta Miceli, Sean O’Rourke, Gianluca Borio, Agnieszka Zienciuk-Krajka, Antonio Curcio,
Andreea Elena Surducan, Mario Colombo, Carlo Napolitano, Silvia G. Priori
Mazzanti and colleagues characterized 73 patients with short QT syndrome (SQTS) who
were enrolled in an international registry. Cardiac arrest (CA) was the most frequent
presenting symptom (40% of probands; age range <1 month to 41 years). The rate of CA
was 4% in the ﬁrst year of life; the probability of a ﬁrst CA by the age of 40 years was 41%.
Despite the male predominance, females had a risk proﬁle superimposable to that of men.
A history of a previous CA was the only predictor of recurrences during follow-up. These
data help to clarify the natural history of SQTS and suggest that it is highly lethal.
Editorial Comment: Martin Tristani-Firouzi, p. 1309DISEASES OF THE AORTAAortic Geometry Change Due to Dissection 1311Bartosz Rylski, Philipp Blanke, Friedhelm Beyersdorf, Nimesh D. Desai, Rita K. Milewski,
Matthias Siepe, Fabian A. Kari, Martin Czerny, Thierry Carrel, Christian Schlensak, Tobias Krüger,
Michael J. Mack, William T. Brinkman, Friedrich W. Mohr, Christian D. Etz, Maximilian Luehr,
Joseph Bavaria
Aortic diameter is the major criterion for elective ascending aortic replacement for dilated
ascending aortas to prevent aortic dissection. However, most recommendations are based on
diameters of aortas that have already been dissected. Rylski and colleagues combined data
from 6 tertiary centers of patients with acute type A aortic dissection who had undergone
computed tomography angiography (CTA) <2 years before and immediately after aortic
dissection onset. A total of 63 patients were included. In all but 1 patient, maximum
ascending aortic diameter was <55 mm on the previous CTA scan. These results show that
the geometry of the thoracic aorta is affected by aortic dissection and suggest the need for
better methods to determine which patients will beneﬁt from elective aorta repair.(continued on page A-34)
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Benedikt Weber, Nikola Cesarovic, Michele Sidler, Jori Leenders, Rolf Jenni, Jürg Grünenfelder,
Volkmar Falk, Frank P. T. Baaijens, Simon P. Hoerstrup
By decellularization of homologous transcatheter tissue-engineered heart valves (TEHVs),
Driessen-Mol and colleagues were able to produce “off-the-shelf” starter matrices that should
be repopulated with endogenous cells after implantation. This concept was tested in an
animal model with the valves placed transapically into the pulmonary position. Valve
functionality immediately after implantation was excellent, with only minor paravalvular
leakage in some animals, but most animals developed moderate regurgitation after 24 weeks.
Signiﬁcant matrix remodeling was observed in the entire valve as was host cell repopulation.
TEHVs may represent an interesting alternative to current prostheses because of their
potential for self-repair.
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